RESCAP platform : Disease modifying therapeutics in Parkinson Disease, Diabetes and Rheumatoid Arthritis. Empowering Innate Immunity
AMRIF focuses on developing safe and well tolerated treatments for chronic inflammatory diseases.
AMRIF is a spin-off company of Alloksys Life Sciences. Leveraging on the RESCAP® platform, we develop therapies for chronic diseases with an underlying problem of systemic inflammation. Our near term focus is on unmet medical disease applications in Neuro Degenerative Diseases (PD, ALZ), arthritis and diabetic complications.
AMRIF’s human recombinant therapeutic protein hRESCAP has completed a Ph l clinical study. Native bRESCAP is applied in several clinical studies.
How we work together with clinicians, hospitals and other institutions to help patients with unmet medical need diseases.
In this video:
- What is RESCAP?
- Our research on protecting barriers and anti-inflammatory action
- More information on our partnerships to transfer our products to the market
We are very proud to work with:
Participating Clinicians and clinical centers and Aix Scientifics as global CRO in ongoing and planned clinical trials as well as investors and Dutch RVO innovation credit facility.